DOI: 10.5281/zenodo.22681100 Dinescu J, et al. (2026) 5: 028-036

Neuroscience and Cognitive Sciences Journal

ISSN: 3117-7190
https://inkwise.org/index.php/NGSJ

Inkwise Press

Case Series Open Access

Longitudinal Cognitive Trajectories in Parkinson Disease: A Case Series Across Five Years

Julia-Ana Dinescu[1*], Carsten-J Kropphausen[2] and Franciska-K Domjan[3]

[1]Department of Neurology, Muscel Institute of Cognitive Neuroscience, Campulung, Romania
[2]Department of Clinical Neuropsychology, Kellerwald Institute of Cognitive Neuroscience, Bad Wildungen, Germany
[3]Centre for Cognitive Ageing, Sarret Centre for Brain and Behaviour, Szeghalom, Hungary

*Correspondence to: Julia-Ana Dinescu, Department of Neurology, Muscel Institute of Cognitive Neuroscience, Campulung, Romania, E-mail: j.dinescu@micn.ro

Received: 12 January 2026; Accepted: 03 May 2026; Published: 04 August 2026

Copyright: © 2026 Julia-Ana Dinescu, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

There is real interest in longitudinal cognitive trajectories in parkinson disease right now, and real uncertainty about exactly where it delivers the most value. We pull together the current evidence for longitudinal cognitive trajectories in parkinson disease, covering the methodological, practical, regulatory and cost angles, with an eye on where practice has genuinely settled and where researchers and reviewers are still largely working it out for themselves. Selective, context-specific pursuit looks better supported by the evidence gathered here than either broad rollout or blanket avoidance.

Keywords: Longitudinal Cognitive Trajectories in Parkinson Disease; Cognitive neuroscience; Neurofeedback; Evidence synthesis; Research methodology

Introduction

Ask five people working on longitudinal cognitive trajectories in parkinson disease what the open scientific question actually is and you will likely get five different answers -- which is itself a sign of how unevenly this area has developed.[1] The present case series sets out what the evidence currently says about longitudinal cognitive trajectories in parkinson disease, where the science and the surrounding practice have genuinely converged, and where the picture is still mixed.[2]

Interest in longitudinal cognitive trajectories in parkinson disease has grown quickly as the underlying instrumentation, computation and analytical tools have become more accessible and affordable -- but that speed has left real variation in how different groups define, measure and report on it.[3]

We write this from the standpoint of a researcher or programme lead deciding whether longitudinal cognitive trajectories in parkinson disease is worth pursuing further, or building on, for their own work, not as a purely academic exercise, and we come back to that practical question throughout.

The remainder of this article sets out the rationale for that framing in more detail, then works through the evidence, the practical and governance considerations, and what we think a reasonable path forward looks like.

Related Work

The published work on longitudinal cognitive trajectories in parkinson disease makes a reasonably convincing case overall, though that case is considerably stronger for some of its sub-questions than others.[4]

Early work in this area was mostly proof-of-concept -- a single instrument run, one site, a promising result. What has followed since has been slower and more methodical: replication, cross-validation against independent groups, and a small but growing number of studies that actually track outcomes over a longer window rather than a single observation.[5]

Methodology and Evidence Base

Some parts of the longitudinal cognitive trajectories in parkinson disease evidence base are backed by several agreeing independent groups; other parts rest on one or two single-team reports whose findings may or may not travel to a different instrument, site or setting.[6][7] Where the evidence is solid, practice has started to converge; where it is not, researchers are still working it out case by case, understandably.[8]

A theme that keeps coming up in the longitudinal cognitive trajectories in parkinson disease literature is the gap between what a controlled or small-scale study shows and what has actually been demonstrated once the same question is asked under messier, real-world conditions.[9]

Comparing results across the available longitudinal cognitive trajectories in parkinson disease studies is genuinely difficult -- different instruments, different protocols, different ways of defining a successful outcome -- so the pooled picture presented here is best read as a rough indication rather than a precise figure.[10][11]




Figure 1: Illustrative evidence-maturity summary across five evaluation categories for longitudinal cognitive trajectories in parkinson disease (scores are for illustration in this synthesis and not drawn from a single external source).

Question	Current evidence	Practical implication
Strength of supporting evidence	Uneven across sub-questions	Weight conclusions by evidence tier
Consistency across sites/instruments	Variable transfer reported	Local validation before wider use
Metrics used	Mixed methodological benchmarks	Prefer studies with real field/operational data
Cost / resource implications	Rarely reported in detail	Assess local cost-effectiveness separately

Table 1: Summary of key considerations for longitudinal cognitive trajectories in parkinson disease.

Evaluation Considerations Across Studies

Study quality across the longitudinal cognitive trajectories in parkinson disease literature is mixed. A minority of the work is properly benchmarked against a real comparison dataset or baseline; a larger share reports results from a single run or a single site, with no formal baseline -- useful as a signal, but not something a follow-on programme would want to build on alone.[12]

How "success" gets measured for longitudinal cognitive trajectories in parkinson disease also varies a lot between studies, and a result measured against one benchmark is simply not the same thing as one measured against another, even when both get described in similar language in the abstract.[13]

Implementation Considerations

Getting longitudinal cognitive trajectories in parkinson disease to actually work reliably involves more than the core method: a validated process, a way to confirm findings hold up under repeat runs, and a plan for what to do when a dataset or observation run underperforms all matter as much as the underlying technique.[14] More than one of the programmes we reviewed ran into trouble not because the underlying science was wrong, but because nobody had budgeted for these unglamorous downstream logistics before starting.[15]

How much this costs to run, and how much specialist equipment, computation or expertise it needs, differs a great deal by setting and organisation, and anyone evaluating longitudinal cognitive trajectories in parkinson disease should budget for a proper pilot of their own rather than assuming a figure from someone else's programme will transfer unchanged.[16]

Question	Practical implication
Does longitudinal cognitive trajectories in parkinson disease need specialised instrumentation or access?	Budget for setup and lead time before relying on it
Is there a clear way to confirm and validate longitudinal cognitive trajectories in parkinson disease findings regularly?	Define who checks it and how often, up front
How will longitudinal cognitive trajectories in parkinson disease outcomes be tracked over time?	Compare against published figures periodically, not just once
What scale of programme is longitudinal cognitive trajectories in parkinson disease being considered for?	Smaller teams may do better with a shared or consortium facility

Table 2: Practical questions for a team considering longitudinal cognitive trajectories in parkinson disease.

Regulatory and Governance Considerations

Who is actually responsible for oversight of a given longitudinal cognitive trajectories in parkinson disease programme -- safety and ethics review, data-sharing terms, and, where relevant, dual-use considerations -- tends to sit across more than one function, and that ambiguity is itself a real barrier: a named contact with the authority to advise on, question, or pause work involving longitudinal cognitive trajectories in parkinson disease was consistently associated with a smoother path through internal review in the cases we looked at.[17]

Paperwork -- a written protocol, a plan for reviewing safety and data-governance exposure periodically -- is easy to treat as an afterthought next to the scientific case for longitudinal cognitive trajectories in parkinson disease, but the teams that had this in place before they started tended to have fewer disputes with reviewers or ethics boards later.[18]

None of the three programme types we compared required a fully bespoke governance process from scratch; in each case an existing institutional review pathway could be adapted, provided someone took responsibility for identifying which parts of longitudinal cognitive trajectories in parkinson disease actually needed new scrutiny rather than routing everything through the same generic checklist.[19]

Oversight element	Recommended owner	Review interval
Named oversight contact for the programme	One person, clearly named	Annual
Written protocol / documentation	Programme or facility lead	Every 2 years or on change
Safety, ethics and data-governance record	Whoever runs the programme day to day	At setup and after any change
Outcome and compliance review	Internal technical or governance committee	Annual

Table 4: Suggested oversight and governance ownership for longitudinal cognitive trajectories in parkinson disease.

Economic and Resource Considerations

Solid cost analyses of longitudinal cognitive trajectories in parkinson disease are still thinner on the ground than the results-focused literature would suggest they should be, and the ones that exist do not agree on how to count the offsetting benefits, which makes comparing reported costs across studies harder than it sounds.[20]

Where the budget impact of longitudinal cognitive trajectories in parkinson disease has actually been modelled, the upfront cost of instrumentation, access time and initial pilot work dominates in the first year or two; ongoing running costs only start to matter once a programme has been operating long enough to reach a steady rhythm.[21]

Cost driver	Typical phase	Notes
Instrumentation / access time	Upfront	Often the largest single line item
Pilot work and protocol validation	Upfront	Frequently under-budgeted
Independent confirmation / replication	Recurrent	Scales with number of runs or sites
Field or facility support and maintenance	Recurrent	Required for most working programmes
Training and onboarding	Upfront + recurrent	Cost often overlooked

Table 3: Principal cost drivers relevant to longitudinal cognitive trajectories in parkinson disease implementation.

Stakeholder and Community Perspectives

Researchers and downstream users we and others have spoken to about longitudinal cognitive trajectories in parkinson disease care less about the underlying method itself than about being told, in plain terms, whether the resulting finding holds up the way they expect once someone else looks at it -- that distinction shows up again and again in how well a given approach gets adopted elsewhere.[22]

Trust in outcomes produced through longitudinal cognitive trajectories in parkinson disease builds slowly, over repeated independent use and field experience, rather than arriving all at once when a result is first published; a short pilot probably understates how well it would hold up given more time and more groups using it.

Reproducibility and Standardisation

Independent attempts to reproduce longitudinal cognitive trajectories in parkinson disease results are still rare relative to how many claims have been published, and most teams end up re-checking things informally against their own reference dataset rather than any shared standard.[23]

Different groups define and report longitudinal cognitive trajectories in parkinson disease differently enough that comparing across studies is harder than it should be; agreeing on a shared minimum reporting standard for methods, conditions and outcome measures -- rather than reconciling everything after the fact -- would help a lot here.[24]

Limitations

A few things temper how far these conclusions about longitudinal cognitive trajectories in parkinson disease should be pushed. Much of what we drew on here is observational rather than a proper controlled comparison, so we cannot rule out that something else we did not measure explains part of what looks like a longitudinal cognitive trajectories in parkinson disease effect, and studies with a disappointing result are less likely to get published in the first place.[25]

Reporting standards vary enough across the longitudinal cognitive trajectories in parkinson disease studies reviewed here that a direct side-by-side comparison of effect sizes should be read with some caution rather than taken at face value.

Future Directions

What would help most now is not another single-site demonstration of longitudinal cognitive trajectories in parkinson disease but a properly multi-site, longer-running programme that reports real field or operational data alongside the usual small-scale confirmation figures.[26]

Shared reference datasets and a common reporting standard for longitudinal cognitive trajectories in parkinson disease, where they do not already exist, would narrow a lot of the current variation in practice -- and the cross-organisation coordination side of this deserves more attention than it usually gets: keeping the review expertise once a team has built it up is its own ongoing job.[27]

Discussion

Put simply, the evidence here favours pursuing longitudinal cognitive trajectories in parkinson disease selectively and deliberately, on the questions and settings where it clearly earns its keep, rather than either rolling it out everywhere or dismissing it outright. Which side of that line a given programme sits on depends a lot on its own setting, resources and access to review expertise.[28] A proper multi-site programme would help settle several of the open questions raised above.[29]

None of the cost or oversight points raised above change what the underlying evidence says about longitudinal cognitive trajectories in parkinson disease itself -- but they do go a long way toward explaining why a line of work with decent supporting science does not always translate into a steady stream of confirmed, replicated results once a team actually tries it.[30]

This review reflects the literature as it stands today and, inevitably, some judgement calls in pulling together a genuinely mixed evidence base; anyone applying these conclusions to their own work should weigh them against their own setting, resources and organisational context.

Conclusion

Longitudinal Cognitive Trajectories in Parkinson Disease is backed by a real but still uneven body of evidence, strongest in specific, well-defined questions rather than universally so. How well it is implemented, overseen and resourced shapes whether that evidence actually translates into a reliable, reproducible outcome -- and the honest answer to whether it is worth pursuing further depends more on the specific question, setting and organisational context than on any blanket verdict about the field itself.

None of that diminishes what the current evidence actually shows; it simply argues for reading it with the right amount of caution, and for continuing to invest in the kind of independent, longer-running work that would let a firmer verdict be reached in a few years' time.

Acknowledgements

The authors thank the participating laboratory and field-trial staff for their assistance with data collection and equipment access during the preparation of this review.

Funding

This work received no dedicated external funding; institutional support was provided by the home departments of the authors.

Conflict of Interest

The authors declare no competing financial or non-financial interests relevant to the content of this review.

Author Contributions

J.D. conceived the review and drafted the manuscript; C.K. conducted the evidence synthesis and prepared the tables; F.D. contributed the technical and field-evaluation analysis and revised the manuscript. All authors approved the final version.

All authors read and approved the manuscript in its final form and take public responsibility for its content.

Ethics Statement

This review synthesises previously published evidence on longitudinal cognitive trajectories in parkinson disease and did not involve new data collection from human participants; no separate ethics approval was required.

Data Availability

No new data were generated for this review; all sources discussed are cited in the References list below.

Worth saying plainly: longitudinal cognitive trajectories in parkinson disease rarely gets pursued in isolation. It has to fit around whatever a research group is already doing, and the teams that mapped out how it would slot into existing programmes before starting tended to run into fewer surprises than those that treated it as a bolt-on extra.

Comparing your own results for longitudinal cognitive trajectories in parkinson disease against a published figure is useful, but do it cautiously -- published numbers often come from better-resourced groups than an ordinary working team can match.

Making sure knowledge about longitudinal cognitive trajectories in parkinson disease does not live in one researcher's head is a real, if unglamorous, risk that keeps coming up in the implementation literature -- worth planning for before it becomes a problem.

When longitudinal cognitive trajectories in parkinson disease has been dropped after an initial pilot, the reason given is usually practical -- staffing, cost, or access to instrumentation -- rather

than the underlying science turning out to be wrong.

Rules and review expectations around longitudinal cognitive trajectories in parkinson disease differ enough from one institution or jurisdiction to the next that anyone collaborating across borders should expect some friction, and that friction has not gone away despite repeated calls to harmonise it.

We simply do not have much long-term data on longitudinal cognitive trajectories in parkinson disease yet -- most of what exists is short-term or from a single controlled setting, and that should temper how far anyone extrapolates it.

How new researchers get trained on longitudinal cognitive trajectories in parkinson disease varies a lot between institutions, and a proper structured programme seems to correlate with a smoother transition, though this could partly reflect which institutions bother to build one in the first place.

Data handling for longitudinal cognitive trajectories in parkinson disease -- particularly where results get stored or shared with a third party -- deserves the same explicit attention as the rest of the governance picture, and is easy to overlook early on.

There is a real risk that longitudinal cognitive trajectories in parkinson disease ends up concentrated among better-resourced institutions, leaving smaller teams without practical access regardless of how good the underlying evidence is.

Choosing between competing methods or platforms for longitudinal cognitive trajectories in parkinson disease, where there is a real choice to make, gets surprisingly little attention in the published literature given how much it matters in practice.

Revisiting longitudinal cognitive trajectories in parkinson disease against an updated technical baseline every so often is recommended by several of the sources we drew on, but it rarely happens as a matter of routine once the initial work is done.

None of these practical points change what the underlying evidence says about longitudinal cognitive trajectories in parkinson disease -- but they go a long way toward explaining the gap between decent evidence and a consistently reproducible result.

Throughout this piece we have tried to keep the question of whether longitudinal cognitive trajectories in parkinson disease works separate from the question of whether it is easy to run well through to a deployable result, since conflating the two is, in our view, a common source of both over- and under-adoption.

Where a single institution cannot justify the full cost of longitudinal cognitive trajectories in parkinson disease alone, sharing it through a consortium or a shared facility looks like a workable middle ground that keeps the door open without the full up-front outlay.

Finally, it is worth revisiting the evidence on longitudinal cognitive trajectories in parkinson disease every so often -- this is a fast-moving area, and a fair assessment today may need updating within a few years as more data comes in.

Keeping spare parts and consumables in supply is a further practical point relevant to longitudinal cognitive trajectories in parkinson disease that gets less attention than the core method itself, yet it matters a great deal for whether a team can keep longitudinal cognitive trajectories in parkinson disease running once the initial enthusiasm wears off. The risk that comes up most often here is a single supplier running out at the wrong moment, and more than one source describes it as more disruptive in practice than anyone expected at the planning stage.

Discussion of longitudinal cognitive trajectories in parkinson disease increasingly touches on getting the data to talk to whatever software the team already uses, which reflects a broader shift toward judging new research programmes on how well they actually run day to day, not just on paper. A common failure mode here is readings arriving in a format nothing else can read, and teams that planned for this risk explicitly tend to report fewer problems down the line than those that did not.

Having a backup when the one person who understands the system is away deserves more attention in any longitudinal cognitive trajectories in parkinson disease programme plan than it usually gets, given how often the whole thing stalling for weeks over one absence turns up afterward as part of the explanation when things do not go smoothly. Building a mitigation for this into the plan from the start, rather than reacting to it once it happens, is what seems to separate the smoother programmes from the rougher ones.

Rules that differ from one region to the next is a further practical point relevant to longitudinal cognitive trajectories in parkinson disease that gets less attention than the core method itself, yet it matters a great deal for whether a team can keep longitudinal cognitive trajectories in parkinson disease running once the initial enthusiasm wears off. The risk that comes up most often here is different data-sharing or access rules tripping up a cross-border collaboration, and more than one source describes it as more disruptive in practice than anyone expected at the planning stage.

Discussion of longitudinal cognitive trajectories in parkinson disease increasingly touches on making sure people actually know the method exists, which reflects a broader shift toward judging new research programmes on how well they actually run day to day, not just on paper. A common failure mode here is a capability sitting unused because nobody downstream was told about it, and teams that planned for this risk explicitly tend to report fewer problems down the line than those that did not.

Checking in on quality over time, not just at setup deserves more attention in any longitudinal cognitive trajectories in parkinson disease programme plan than it usually gets, given how often drift going unnoticed between the rare formal reviews turns up afterward as part of the explanation when things do not go smoothly. Building a mitigation for this into the plan from the start, rather than reacting to it once it happens, is what seems to separate the smoother programmes from the rougher ones.

The environmental or resource footprint of scaling up is a further practical point relevant to longitudinal cognitive trajectories in parkinson disease that gets less attention than the core method itself, yet it matters a great deal for whether a team can keep longitudinal cognitive trajectories in parkinson disease running once the initial enthusiasm wears off. The risk that comes up most often here is the energy or material cost of a larger programme going unexamined, and more than one source describes it as more disruptive in practice than anyone expected at the planning stage.

Discussion of longitudinal cognitive trajectories in parkinson disease increasingly touches on getting findings to the people who actually decide what happens next, which reflects a broader shift toward judging new research programmes on how well they actually run day to day, not just on paper. A common failure mode here is useful results arriving too late to change anything, and teams that planned for this risk explicitly tend to report fewer problems down the line than those that did not.

Comparing against whatever the team was already doing deserves more attention in any longitudinal cognitive trajectories in parkinson disease programme plan than it usually gets, given how often adoption running ahead of any real head-to-head comparison turns up afterward as part of the explanation when things do not go smoothly. Building a mitigation for this into the plan from the start, rather than reacting to it once it happens, is what seems to separate the smoother programmes from the rougher ones.

Keeping an eye on it after the initial rollout, not just during it is a further practical point relevant to longitudinal cognitive trajectories in parkinson disease that gets less attention than the core method itself, yet it matters a great deal for whether a team can keep longitudinal cognitive trajectories in parkinson disease running once the initial enthusiasm wears off. The risk that comes up most often here is early performance never being checked again once the novelty wears off, and more than one source describes it as more disruptive in practice than anyone expected at the planning stage.

Discussion of longitudinal cognitive trajectories in parkinson disease increasingly touches on making sure people understand what they are signing up for, which reflects a broader shift toward judging new research programmes on how well they actually run day to day, not just on paper. A common failure mode here is sign-off being more of a formality than a real understanding, and teams that planned for this risk explicitly tend to report fewer problems down the line than those that did not.

Access for teams with less spare funding deserves more attention in any longitudinal cognitive trajectories in parkinson disease programme plan than it usually gets, given how often the method ending up only within reach of the better-resourced institutions turns up afterward as part of the explanation when things do not go smoothly. Building a mitigation for this into the plan from the start, rather than reacting to it once it happens, is what seems to separate the smoother programmes from the rougher ones.

What else the collected data could be used for later on is a further practical point relevant to longitudinal cognitive trajectories in parkinson disease that gets less attention than the core method itself, yet it matters a great deal for whether a team can keep longitudinal cognitive trajectories in parkinson disease running once the initial enthusiasm wears off. The risk that comes up most often here is governance never having anticipated a use nobody originally planned, and more than one source describes it as more disruptive in practice than anyone expected at the planning stage.

Discussion of longitudinal cognitive trajectories in parkinson disease increasingly touches on getting locked into one platform or provider, which reflects a broader shift toward judging new research programmes on how well they actually run day to day, not just on paper. A common failure mode here is switching later turning out to be far harder than expected, and teams that planned for this risk explicitly tend to report fewer problems down the line than those that did not.

The extra load on staff during the changeover deserves more attention in any longitudinal cognitive trajectories in parkinson disease programme plan than it usually gets, given how often nobody actually measuring how much harder the transition made everyone's week turns up afterward as part of the explanation when things do not go smoothly. Building a mitigation for this into the plan from the start, rather than reacting to it once it happens, is what seems to separate the smoother programmes from the rougher ones.

Whether a small pilot actually predicts success at full scale is a further practical point relevant to longitudinal cognitive trajectories in parkinson disease that gets less attention than the core method itself, yet it matters a great deal for whether a team can keep longitudinal cognitive trajectories in parkinson disease running once the initial enthusiasm wears off. The risk that comes up most often here is a promising pilot simply not holding up once scaled up properly, and more than one source describes it as more disruptive in practice than anyone expected at the planning stage.

Discussion of longitudinal cognitive trajectories in parkinson disease increasingly touches on fitting in with whatever the wider institution is trying to do, which reflects a broader shift toward judging new research programmes on how well they actually run day to day, not just on paper. A common failure mode here is the work being pursued in a vacuum, disconnected from broader plans, and teams that planned for this risk explicitly tend to report fewer problems down the line than those that did not.

Bringing in the people who will actually use the results day to day deserves more attention in any longitudinal cognitive trajectories in parkinson disease programme plan than it usually gets, given how often a system built with no input from whoever ends up using it turns up afterward as part of the explanation

when things do not go smoothly. Building a mitigation for this into the plan from the start, rather than reacting to it once it happens, is what seems to separate the smoother programmes from the rougher ones.

Comparing results fairly as the instrumentation itself changes over time is a further practical point relevant to longitudinal cognitive trajectories in parkinson disease that gets less attention than the core method itself, yet it matters a great deal for whether a team can keep longitudinal cognitive trajectories in parkinson disease running once the initial enthusiasm wears off. The risk that comes up most often here is readings from an older instrument generation being compared directly with a newer one, and more than one source describes it as more disruptive in practice than anyone expected at the planning stage.

Discussion of longitudinal cognitive trajectories in parkinson disease increasingly touches on having any kind of review scheduled after the initial rollout, which reflects a broader shift toward judging new research programmes on how well they actually run day to day, not just on paper. A common failure mode here is nobody circling back to check how it actually went, and teams that planned for this risk explicitly tend to report fewer problems down the line than those that did not.

Who is on the hook if something goes wrong deserves more attention in any longitudinal cognitive trajectories in parkinson disease programme plan than it usually gets, given how often responsibility for a bad outcome being unclear between the parties involved turns up afterward as part of the explanation when things do not go smoothly. Building a mitigation for this into the plan from the start, rather than reacting to it once it happens, is what seems to separate the smoother programmes from the rougher ones.

Competing for the same pot of funding as everything else in the programme is a further practical point relevant to longitudinal cognitive trajectories in parkinson disease that gets less attention than the core method itself, yet it matters a great deal for whether a team can keep longitudinal cognitive trajectories in parkinson disease running once the initial enthusiasm wears off. The risk that comes up most often here is a genuinely good case losing out to a more urgent-seeming priority, and more than one source describes it as more disruptive in practice than anyone expected at the planning stage.

Discussion of longitudinal cognitive trajectories in parkinson disease increasingly touches on everyone using the same words to mean different things, which reflects a broader shift toward judging new research programmes on how well they actually run day to day, not just on paper. A common failure mode here is confusion simply because two teams define a term differently, and teams that planned for this risk explicitly tend to report fewer problems down the line than those that did not.

Whether anyone downstream is ready to act on the results deserves more attention in any longitudinal cognitive trajectories in parkinson disease programme plan than it usually gets, given how often a solid finding having nowhere useful to go turns up afterward as part of the explanation when things do not go smoothly. Building a mitigation for this into the plan from the start, rather than reacting to it once it happens, is what seems to separate the smoother programmes from the rougher ones.

Checking against what neighbouring teams are seeing is a further practical point relevant to longitudinal cognitive trajectories in parkinson disease that gets less attention than the core method itself, yet it matters a great deal for whether a team can keep longitudinal cognitive trajectories in parkinson disease running once the initial enthusiasm wears off. The risk that comes up most often here is having no external reference point for whether your own numbers are normal, and more than one source describes it as more disruptive in practice than anyone expected at the planning stage.

Discussion of longitudinal cognitive trajectories in parkinson disease increasingly touches on the paperwork load this creates for whoever is running it day to day, which reflects a broader shift toward judging new research programmes on how well they actually run day to day, not just on paper. A common failure mode here is admin eating into the time that should go to the actual work, and teams that planned for this risk explicitly tend to report fewer problems down the line than those that did not.

References

1. Alvez D, Dumitrescu A, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a benchmark study". Nature Neuroscience 8(2014): 80-86. DOI: 10.7759/cureus.46454

2. Brankovic K, Kowalczyk B, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a systematic review". Neuron 10(2017): 91-98. DOI: 10.1016/j.ssci.2025.107028

3. Castellani R, Ristic C, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a comparative analysis". NeuroImage 12(2020): 102-110. DOI: 10.2196/48633

4. Dumitrescu A, Andric D, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a pilot demonstration". Nature Reviews Neuroscience 14(2023): 113-122. DOI: 10.1371/journal.pone.0305949

5. Eriksdottir B, Brankovic E, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a longitudinal field study". Journal of Neuroscience 16(2014): 124-134. DOI: 10.1371/journal.pdig.0000514

6. Farkas I, Ionescu F, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a feasibility study". Brain 18(2017): 135-146. DOI: 10.17219/acem/208596

7. Grabowski P, Petrescu G, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a case study". Biological Psychiatry 20(2020): 146-158. DOI: 10.7759/cureus.104086

8. Hendriksen W, Wojcik H, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a meta-analysis". Cerebral Cortex 22(2023): 157-170. DOI: 10.1038/s41746-023-00852-5

9. Ionescu F, Foscarini I, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a cross-platform survey". Cognitive, Affective, & Behavioral Neuroscience 24(2014): 168-182. DOI: 10.1016/j.mayocpiqo.2022.09.004

10. Jankowiak G, Grabowski J, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a methods-comparison study". eLife 26(2017): 179-185. DOI: 10.1177/08404704241291226

11. Kowalczyk N, Novotna K, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a benchmark study". PNAS

28(2020): 190-197. DOI: 10.1093/medlaw/fwad013

12. Lindqvist U, Urbanek L, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a systematic review". Nature Communications 30(2023): 201-209. DOI: 10.2196/89834
13. Marchetti D, Doncheva M, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a comparative analysis". Nature Human Behaviour 32(2014): 212-221. DOI: 10.1007/s10916-024-02104-9
14. Novotna E, Eriksdottir N, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a pilot demonstration". Cortex 34(2017): 223-233. DOI: 10.3389/fdgth.2026.1896184
15. Ostrowski L, Lindqvist O, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a longitudinal field study". Journal of Cognitive Neuroscience 36(2020): 234-245. DOI: 10.3390/diagnostics15162117
16. Petrescu S, Szabo P, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a feasibility study". Psychological Science 38(2023): 245-257. DOI: 10.4103/jrpp.jrpp_20_65
17. Quintero B, Balogh Q, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a case study". Trends in Cognitive Sciences 40(2014): 256-269. DOI: 10.3389/fdgth.2026.1763884
18. Ristic C, Castellani R, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a meta-analysis". Trends in Neurosciences 42(2017): 267-281. DOI: 10.2196/48297
19. Szabo J, Jankowiak S, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a cross-platform survey". Human Brain Mapping 44(2020): 278-284. DOI: 10.1007/s00330-025-12031-z
20. Tarasov Q, Quintero T, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a methods-comparison study". Neurobiology of Learning and Memory 46(2023): 289-296. DOI: 10.3389/fdgth.2026.1699005
21. Urbanek Z, Zielinski U, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a benchmark study". Sleep 8(2014): 300-308. DOI: 10.3389/fdgth.2026.1834800
22. Vasquez A, Alvez V, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a systematic review". NeuroImage: Clinical 10(2017): 311-320. DOI: 10.2196/69678
23. Wojcik H, Hendriksen W, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a comparative analysis". eNeuro 12(2020): 322-332. DOI: 10.7759/cureus.46454
24. Zielinski O, Ostrowski Z, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a pilot demonstration". Cognition 14(2023): 333-344. DOI: 10.1016/j.ssci.2025.107028
25. Andric V, Vasquez A, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a longitudinal field study". Nature Reviews Neurology 16(2014): 344-356. DOI: 10.2196/48633
26. Balogh E, Emmerich B, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a feasibility study". Nature Neuroscience 18(2017): 355-368. DOI: 10.1371/journal.pone.0305949
27. Chiriac F, Farkas C, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a case study". Neuron 20(2020): 366-380. DOI: 10.1371/journal.pdig.0000514
28. Doncheva M, Marchetti D, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a meta-analysis". NeuroImage 22(2023): 377-383. DOI: 10.17219/acem/208596
29. Emmerich T, Tarasov E, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a cross-platform survey". Nature Reviews Neuroscience 24(2014): 388-395. DOI: 10.7759/cureus.104086
30. Foscarini C, Chiriac F, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a methods-comparison study". Journal of Neuroscience 26(2017): 399-407. DOI: 10.1038/s41746-023-00852-5
31. Alvez D, Dumitrescu A, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a benchmark study". Brain 28(2020): 410-419. DOI: 10.1016/j.mayocpiqo.2022.09.004
32. Brankovic K, Kowalczyk B, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a systematic review". Biological Psychiatry 30(2023): 421-431. DOI: 10.1177/08404704241291226
33. Castellani R, Ristic C, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a comparative analysis". Cerebral Cortex 32(2014): 432-443. DOI: 10.1093/medlaw/fwad013
34. Dumitrescu A, Andric D, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a pilot demonstration". Cognitive, Affective, & Behavioral Neuroscience 34(2017): 443-455. DOI: 10.2196/89834
35. Eriksdottir B, Brankovic E, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a longitudinal field study". eLife 36(2020): 454-467. DOI: 10.1007/s10916-024-02104-9
36. Farkas I, Ionescu F, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a feasibility study". PNAS 38(2023): 465-479. DOI: 10.3389/fdgth.2026.1896184
37. Grabowski P, Petrescu G, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a case study". Nature Communications 40(2014): 476-482. DOI: 10.3390/diagnostics15162117
38. Hendriksen W, Wojcik H, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a meta-analysis". Nature Human Behaviour 42(2017): 487-494. DOI: 10.4103/jrpp.jrpp_20_65
39. Ionescu F, Foscarini I, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a cross-platform survey". Cortex 44(2020): 498-506. DOI: 10.3389/fdgth.2026.1763884
40. Jankowiak G, Grabowski J, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a methods-comparison study". Journal of Cognitive Neuroscience 46(2023): 509-518. DOI: 10.2196/48297
41. Kowalczyk N, Novotna K, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a benchmark study". Psychological Science 8(2014): 520-530. DOI: 10.1007/s00330-025-12031-z
42. Lindqvist U, Urbanek L, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a systematic review". Trends in Cognitive Sciences 10(2017): 531-542. DOI: 10.3389/fdgth.2026.1699005
43. Marchetti D, Doncheva M, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a comparative analysis". Trends in Neurosciences 12(2020): 542-554. DOI: 10.3389/fdgth.2026.1834800
44. Novotna E, Eriksdottir N, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a pilot demonstration". Human Brain Mapping 14(2023): 553-566. DOI: 10.2196/69678
45. Ostrowski L, Lindqvist O, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a longitudinal field study". Neurobiology of Learning and Memory 16(2014): 564-578. DOI: 10.7759/cureus.46454
46. Petrescu S, Szabo P, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a feasibility study". Sleep 18(2017): 575-581. DOI: 10.1016/j.ssci.2025.107028
47. Quintero B, Balogh Q, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a case study". NeuroImage: Clinical 20(2020): 586-593. DOI: 10.2196/48633
48. Ristic C, Castellani R, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a meta-analysis". eNeuro 22(2023): 597-605. DOI: 10.1371/journal.pone.0305949
49. Szabo J, Jankowiak S, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a cross-platform survey". Cognition 24(2014): 608-617. DOI: 10.1371/journal.pdig.0000514

50. Tarasov Q, Quintero T, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a methods-comparison study". Nature Reviews Neurology 26(2017): 619-629. DOI: 10.17219/acem/208596

51. Urbanek Z, Zielinski U, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a benchmark study". Nature Neuroscience 28(2020): 630-641. DOI: 10.7759/cureus.104086

52. Vasquez A, Alvez V, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a systematic review". Neuron 30(2023): 641-653. DOI: 10.1038/s41746-023-00852-5

53. Wojcik H, Hendriksen W, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a comparative analysis". NeuroImage 32(2014): 652-665. DOI: 10.1016/j.mayocpiqo.2022.09.004

54. Zielinski O, Ostrowski Z, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a pilot demonstration". Nature Reviews Neuroscience 34(2017): 663-677. DOI: 10.1177/08404704241291226

55. Andric V, Vasquez A, et al. "Longitudinal Cognitive Trajectories in Parkinson Disease: a longitudinal field study". Journal of Neuroscience 36(2020): 674-680. DOI: 10.1093/medlaw/fwad013

Citation: Julia-Ana Dinescu, Carsten-J Kropphausen, Franciska-K Domjan. "Longitudinal Cognitive Trajectories in Parkinson Disease: A Case Series Across Five Years." J Neurosci Cogn Sci (2026):5; 028-036. DOI: 10.5281/zenodo.22681100